Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Recruiting now · Phase 2

Conditions studied: Multiple Myeloma Refractory, Multiple Myeloma in Relapse

In brief

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Key facts

Study ID

NCT07096778

Run by

CellCentric Ltd.

People needed

100

Starts

2026-01-22

Expected to finish

2029-12-01

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥18 years of age
• Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
• Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
• Adequate hematological, renal and hepatic function
• Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners

You may not qualify if…

• Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
• Prior treatment with p300/CBP bromodomain inhibitors
• Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
• Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
• Major surgery within 4 weeks of the first dose of study treatment
• Live vaccine within 4 weeks of study treatment
• Active or unresolved adverse events
• Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
• Female patients who are pregnant or breast-feeding at any time during the study
• Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

Where it is running

• Mayo Clinic Arizona — Phoenix, Arizona, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• Mayo Clinic Florida — Jacksonville, Florida, United States (enrolling)
• H Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States (enrolling)
• Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
• University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
• American Oncology Partners, PA — Bethesda, Maryland, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
• University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
• Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States (enrolling)
• Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
• University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
• Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
• The Christie NHS Foundation Trust — Withington, Greater Manchester, United Kingdom (enrolling)
• Royal Marsden NHS Foundation Trust — Sutton, London, United Kingdom (enrolling)
• University Hospital of Wales — Cardiff, Wales, United Kingdom (enrolling)
• The Clatterbridge Cancer Centre NHS Foundation Trust — Bebington, Wirral, United Kingdom (enrolling)
• Western General Hospital — Edinburgh, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.